公开(公告)号：US12128069B2

公开(公告)日：2024-10-29

申请号：US15568683

申请日：2016-04-22

申请人： Novartis AG ,  The Trustees of the University of Pennsylvania

发明人： Steven M. Albelda

IPC分类号： A61K35/17 ,  A61K9/00 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725 ,  C07K16/32 ,  C12N5/0783 ,  C12N15/85 ,  A61K45/06 ,  C12N7/00

CPC分类号： A61K35/17 ,  A61K9/0019 ,  A61K38/1709 ,  A61K38/177 ,  A61K38/1774 ,  A61K39/0011 ,  A61K39/001102 ,  A61K39/001104 ,  A61K39/001111 ,  A61K39/001112 ,  A61K39/001117 ,  A61K39/001124 ,  A61K39/001156 ,  A61K39/001157 ,  A61K39/00117 ,  A61K39/00118 ,  A61K39/001182 ,  A61K39/001184 ,  A61K39/00119 ,  A61K39/001193 ,  A61K39/39558 ,  C07K14/47 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/32 ,  C12N15/85 ,  A61K2039/5154 ,  A61K2039/54 ,  A61K2039/572 ,  A61K45/06 ,  C07K14/70578 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2319/02 ,  C07K2319/03 ,  C07K2319/035 ,  C12N5/0637 ,  C12N7/00 ,  C12N2510/00 ,  C12N2740/15043

摘要： The invention provides compositions and methods for treating diseases associated with expression of a cancer associated antigen as described herein. The invention also relates to chimeric antigen receptor (CAR) specific to a cancer associated antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a cancer associated antigen as described herein.

公开(公告)号：US12023379B2

公开(公告)日：2024-07-02

申请号：US17132320

申请日：2020-12-23

申请人： Emory University

发明人： Periasamy Selvaraj

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61K39/385 ,  A61K39/39 ,  A61K39/395 ,  A61P35/00

CPC分类号： A61K39/385 ,  A61K39/0011 ,  A61K39/001102 ,  A61K39/001106 ,  A61K39/001124 ,  A61K39/001129 ,  A61K39/00117 ,  A61K39/001172 ,  A61K39/001173 ,  A61K39/001182 ,  A61K39/00119 ,  A61K39/001191 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61K39/39 ,  A61K2039/515 ,  A61K2039/5152 ,  A61K2039/5258 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55522 ,  A61K2039/55533 ,  A61K2039/55538 ,  A61K2039/55561 ,  A61K2039/55572 ,  A61K2039/6018 ,  A61K2039/62 ,  A61K2039/627

摘要： In some embodiments, described herein is a method of tumor treatment or tumor vaccination. The method generally comprises applying to a human being in need thereof a tumor therapeutic composition or tumor vaccine defined herein. The tumor therapeutic composition or tumor vaccine can be produced by protein transfer of glycosyl-phosphatidylinositol (GPI)-anchored immunostimulatory or costimulatory molecules.

公开(公告)号：US20240156961A1

公开(公告)日：2024-05-16

申请号：US18334820

申请日：2023-06-14

申请人： BioNTech US Inc.

发明人： Michael Steven Rooney ,  Lauren Elizabeth Stopfer

IPC分类号： A61K39/00 ,  A61P35/00 ,  A61P37/04 ,  C12N5/0783

CPC分类号： A61K39/4632 ,  A61K39/0011 ,  A61K39/001193 ,  A61K39/4611 ,  A61K39/4644 ,  A61P35/00 ,  A61P37/04 ,  C12N5/0636 ,  A61K2039/53 ,  C12N2501/2301 ,  C12N2501/2307 ,  C12N2501/2315 ,  C12N2501/25 ,  C12N2501/26

摘要： Provided herein are compositions relating to tissue-specific antigens, and methods for identifying tissue-specific antigens. Also provided herein are pharmaceutical compositions and methods of treatment that relate to tissue-specific antigens.

公开(公告)号：US11980659B2

公开(公告)日：2024-05-14

申请号：US17360342

申请日：2021-06-28

申请人： The Trustees of the University of Pennsylvania ,  Inovio Pharmaceuticals, Inc.

发明人： David Weiner ,  Jian Yan ,  Bernadette Ferraro ,  Niranjan Y. Sardesai ,  Mathura P. Ramanathan

IPC分类号： A61K38/00 ,  A61K39/00 ,  C07K14/47 ,  C12N9/48 ,  C12N9/64

CPC分类号： A61K39/001193 ,  A61K39/0011 ,  A61K39/001194 ,  A61K39/001195 ,  C07K14/4748 ,  C12N9/485 ,  C12N9/6424 ,  C12Y116/01 ,  C12Y304/17021 ,  C12Y304/21077 ,  A61K39/00 ,  A61K2039/53 ,  A61K2039/884

摘要： Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.

公开(公告)号：US20240101626A1

公开(公告)日：2024-03-28

申请号：US18546306

申请日：2022-02-11

申请人： Kar MUTHUMANI ,  David WEINER ,  The Wistar Institute of Anatomy and Biology

发明人： Kar Muthumani ,  David Weiner

IPC分类号： C07K14/47 ,  A61K39/00 ,  A61P37/04 ,  C12N9/16

CPC分类号： C07K14/4748 ,  A61K39/001193 ,  A61P37/04 ,  C12N9/16 ,  C12Y301/03002 ,  A61K39/00 ,  A61K2039/53

摘要： The present invention provides consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PAP, PARM, PCTA, PSCA, PSP94, and STEAP antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PAP, PARM, PCTA, PSCA, PSP94, and STEAP antigens, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.

公开(公告)号：US11680244B2

公开(公告)日：2023-06-20

申请号：US15575073

申请日：2016-05-19

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Christopher S. Seet ,  Gay Miriam Crooks

IPC分类号： C12N5/10 ,  C12N5/0784 ,  A61K39/00

CPC分类号： C12N5/0639 ,  A61K39/0011 ,  A61K39/00115 ,  A61K39/00117 ,  A61K39/001104 ,  A61K39/001106 ,  A61K39/001108 ,  A61K39/001109 ,  A61K39/001122 ,  A61K39/001149 ,  A61K39/001151 ,  A61K39/001153 ,  A61K39/001156 ,  A61K39/001157 ,  A61K39/001164 ,  A61K39/001168 ,  A61K39/001171 ,  A61K39/001172 ,  A61K39/001182 ,  A61K39/001186 ,  A61K39/001188 ,  A61K39/001191 ,  A61K39/001192 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61K39/001197 ,  A61K2039/5154 ,  C12N2500/30 ,  C12N2501/125 ,  C12N2501/145 ,  C12N2501/22 ,  C12N2501/2303 ,  C12N2501/26 ,  C12N2501/42 ,  C12N2501/998 ,  C12N2502/1121 ,  C12N2502/1171 ,  C12N2502/1352

摘要： In various embodiments methods of producing a cell population enriched for CLEC9A+ dendritic cells are provided where the methods involve culturing stem cells and/or progenitor cells in a cell culture comprising culture medium, a notch ligand, stem cell factor (SCF), FLT3 ligand (FLT3L); thrombopoietin (TPO); and IL-3 and/or GMCSF.

公开(公告)号：US12048738B2

公开(公告)日：2024-07-30

申请号：US16548112

申请日：2019-08-22

申请人： CureVac SE

发明人： Jochen Probst ,  Ingmar Hoerr ,  Thomas Lander

IPC分类号： A61K39/00 ,  A61K39/39

CPC分类号： A61K39/001193 ,  A61K39/00 ,  A61K39/001194 ,  A61K39/001195 ,  A61K39/39 ,  A61K2039/53 ,  A61K2039/55516 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/70

摘要： The present invention relates to an active (immunostimulatory) composition comprising at least one RNA, preferably an mRNA, encoding at least two (preferably different) antigens capable of eliciting an (adaptive) immune response in a mammal wherein the antigens are selected from the group consisting of PSA (Prostate-Specific Antigen), PSMA (Prostate-Specific Membrane Antigen), PSCA (Prostate Stem Cell Antigen), and STEAP (Six Transmembrane Epithelial Antigen of the Prostate), The invention furthermore relates to a vaccine comprising an active (immunostimulatory) composition, and to the use of the active (immunostimulatory) composition (for the preparation of a vaccine) and/or of the vaccine for eliciting an (adaptive) immune response for the treatment of prostate cancer (PCa), preferably of neoadjuvant and/or hormone-refractory prostate cancers, and diseases or disorders related thereto. Finally, the invention relates to kits, particularly to kits of parts, containing the active (immunostimulatory) composition and/or the vaccine.

公开(公告)号：US20240174724A1

公开(公告)日：2024-05-30

申请号：US18283369

申请日：2022-03-22

申请人： Hookipa Biotech GmbH

发明人： Igor Matushansky ,  Andy Hwang ,  Kianoosh Katchar ,  Henning Lauterbach ,  Klaus Orlinger ,  Sarah Schmidt ,  Felix Stemeseder

IPC分类号： C07K14/47 ,  A61K39/00 ,  A61P37/04 ,  C12N7/00 ,  C12N9/16

CPC分类号： C07K14/4748 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61P37/04 ,  C12N7/00 ,  C12N9/16 ,  C12Y301/03002 ,  A61K2039/5256 ,  A61K2039/55511 ,  C12N2760/10034 ,  C12N2760/10043

摘要： The present application relates to arenaviruses expressing prostate cancer-related antigens. In particular, described herein is a modified arenavirus particle which is engineered to carry a heterologous open reading frame (ORF) encoding a prostate cancer-related antigen or an antigenic fragment thereof, wherein the prostate cancer-related antigen is selected from the group consisting of: prostatic acid phosphatase (PAP), prostate specific antigen (PSA), and prostate-specific membrane antigen (PSMA). Also described herein are arenavius genome segments or S segments encoding the prostate cancer-related antigen or an antigenic fragment thereof, cDNA, DNA expression vector, a pharmaceutical composition comprising such an arenavirus particle, methods of generating such an arenavirus particle and treating prostate cancer using such an arenavirus particle, and a kit for such usage.

公开(公告)号：US11987613B2

公开(公告)日：2024-05-21

申请号：US16876419

申请日：2020-05-18

申请人： University of Virginia Patent Foundation

发明人： Angela L. Ambakhutwala ,  Victor H. Engelhard ,  Kara L. Cummings ,  Rebecca C. Obeng

IPC分类号： A61P35/00 ,  A61K35/17 ,  A61K38/17 ,  A61K38/19 ,  A61K39/00 ,  A61K45/06 ,  A61K47/64 ,  C07K14/725 ,  C07K16/28 ,  G01N33/50 ,  G01N33/566 ,  G01N33/569 ,  G01N33/574

CPC分类号： C07K14/7051 ,  A61K35/17 ,  A61K38/1774 ,  A61K38/19 ,  A61K39/0011 ,  A61K39/001106 ,  A61K39/00111 ,  A61K39/001132 ,  A61K39/001151 ,  A61K39/001156 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001181 ,  A61K39/001182 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001188 ,  A61K39/001189 ,  A61K39/001191 ,  A61K39/001192 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61K39/001197 ,  A61K45/06 ,  A61K47/6425 ,  C07K16/2809 ,  G01N33/505 ,  G01N33/566 ,  G01N33/56977 ,  G01N33/574 ,  G01N33/57484 ,  A61K2039/5158 ,  A61K2039/55533 ,  C07K2317/76 ,  A61K38/19 ,  A61K2300/00 ,  A61K38/1774 ,  A61K2300/00 ,  A61K35/17 ,  A61K2300/00

摘要： Provided are isolated TCRs, TCR-like molecules, and portions thereof that bind to phosphopeptide-HLA-A2 complexes. The isolated TCRs, TCR-like molecules, or portions are optionally soluble TCRs, TCR-like molecules, or portions. Also provided are isolated nucleic acids encoding the disclosed TCRs, TCR-like molecules, or portions; host cells that contain the disclosed TCRs, TCR-like molecules, or portions; pharmaceutical compositions that include the disclosed TCRs, TCR-like molecules, portions, nucleic acids, and/or T cells; kits; and methods of using the same.

公开(公告)号：US20240115679A1

公开(公告)日：2024-04-11

申请号：US18529758

申请日：2023-12-05

申请人： The Regents of the University of Michigan

发明人： James J. Moon ,  Rui Kuai ,  Anna A. Schwendeman ,  Jutaek Nam

IPC分类号： A61K39/00 ,  A61K9/127 ,  A61K31/7088 ,  A61K31/712 ,  A61K31/713 ,  A61K45/06 ,  A61K47/54 ,  A61K47/69 ,  C12N15/11 ,  C12N15/113

CPC分类号： A61K39/0011 ,  A61K9/127 ,  A61K31/7088 ,  A61K31/712 ,  A61K31/713 ,  A61K39/001106 ,  A61K39/00111 ,  A61K39/001132 ,  A61K39/001151 ,  A61K39/001156 ,  A61K39/001157 ,  A61K39/001162 ,  A61K39/001164 ,  A61K39/001166 ,  A61K39/001176 ,  A61K39/001181 ,  A61K39/001182 ,  A61K39/001184 ,  A61K39/001186 ,  A61K39/001188 ,  A61K39/001189 ,  A61K39/001191 ,  A61K39/001192 ,  A61K39/001193 ,  A61K39/001194 ,  A61K39/001195 ,  A61K39/001197 ,  A61K45/06 ,  A61K47/554 ,  A61K47/6917 ,  C12N15/111 ,  C12N15/113 ,  C12N2310/14 ,  C12N2310/3515 ,  C12N2320/32

摘要： The present invention relates to nanoparticles complexed with biomacromolecule agents configured for treating, preventing or ameliorating various types of disorders, and methods of synthesizing the same. In particular, the present invention is directed to compositions comprising nanoparticles (e.g., synthetic high density lipoprotein (sHDL)) carrying biomacromolecule agents (e.g., nucleic acid, peptides, glycolipids, etc.), methods for synthesizing such nanoparticles, as well as systems and methods utilizing such nanoparticles (e.g., in diagnostic and/or therapeutic settings).